Correlative data from an ongoing Phase 1, multicenter study of SENTI-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML) is consistent with its clinical activity and unique logic gated mechanism of action

American Society of Hematology (ASH) Annual Meeting 2025
Muharrem Muftuoglu, Enping Hong, Nosha Farhadfar, Stephen A. Strickland, Ashish R. Bajel, Alireza Eghtedar, Gary Schiller, Mahesh Basyal, Li Li, Lawrence Naitmazi, Rochelle Emery, Timothy Lu, Brian S. Garrison, Kanya Rajangam, Farhad Ravandi, Michael Andreeff

View PDF